MoonLake is developing Sonelokimab primarily for hidradenitis suppurativa (HS), a chronic inflammatory skin condition with limited effective treatments.
With the US population aging rapidly, three healthcare ETFs offer exposure to companies developing treatments, drugs and medical devices for age-related conditions.